← GLP-1 receptor agonists × body weight & composition

SynthesisThe Journal of clinical endocrinology and metabolism2022

An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression.

Ildiko Lingvay et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 2022

Not counted

Probably lowered body weight & composition

−3.29kg−4.62 to −1.96

As reported

difference −3.29 kg, 95% CI −4.62 to −1.96

Not counted

Probably raised glycemic control

2.2×1.1× to 3.9×

Bigger than 5 in 10 for glycemic control

As reported

OR 2.23, 95% CI 1.15–3.90

Range includes no effect

No clear effect on glycemic control

1.6×0.8× to 2.8×

Bigger than 3 in 10 for glycemic control

As reported

OR 1.58, 95% CI 0.82–2.78

Three numbers in the abstract

the abstract, start to end

… 3.0 mg and 4.5 mg with ETDs of -3.29 kg (95% CrI, -4.62 to -1.96) …

… vs dulaglutide 3.0 mg (odds ratio [OR]: 2.23 [95% CrI, 1.15-3.90]), whereas this did not reach significance for semaglutide 2.0 mg vs dulaglutide 4.5 mg (OR: 1.58 [95% CrI, 0.82-2.78]).

← favours treatmentfavours comparator →
could be chance
Body weight & composition
−3.29−4.62 to −1.96
Glycemic control
OR 2.231.15–3.90
Glycemic control
OR 1.580.82–2.78
GLP-1 receptor agonistsGlycemic controlBody weight & composition
1 / 3

6 papers cite it

2022
2023
2024
2025
this paperpooled itcites it
Full record →Abstract, authors, funding and every citing paper · PMID 34922383